JPWO2022196701A1 - - Google Patents

Info

Publication number
JPWO2022196701A1
JPWO2022196701A1 JP2023507138A JP2023507138A JPWO2022196701A1 JP WO2022196701 A1 JPWO2022196701 A1 JP WO2022196701A1 JP 2023507138 A JP2023507138 A JP 2023507138A JP 2023507138 A JP2023507138 A JP 2023507138A JP WO2022196701 A1 JPWO2022196701 A1 JP WO2022196701A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023507138A
Other languages
Japanese (ja)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2022196701A1 publication Critical patent/JPWO2022196701A1/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023507138A 2021-03-16 2022-03-15 Pending JPWO2022196701A1 (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021042670 2021-03-16
PCT/JP2022/011710 WO2022196701A1 (ja) 2021-03-16 2022-03-15 濾胞性t細胞を用いた新規医療技術

Publications (1)

Publication Number Publication Date
JPWO2022196701A1 true JPWO2022196701A1 (cg-RX-API-DMAC7.html) 2022-09-22

Family

ID=83322131

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023507138A Pending JPWO2022196701A1 (cg-RX-API-DMAC7.html) 2021-03-16 2022-03-15

Country Status (5)

Country Link
US (1) US20240159738A1 (cg-RX-API-DMAC7.html)
EP (1) EP4310171A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2022196701A1 (cg-RX-API-DMAC7.html)
CN (1) CN117441103A (cg-RX-API-DMAC7.html)
WO (1) WO2022196701A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021246047A1 (ja) * 2020-06-04 2021-12-09 富士フイルム株式会社 経過予測装置、方法およびプログラム

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2281838A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
WO1998055609A1 (en) 1997-06-06 1998-12-10 The Regents Of The University Of California Inhibitors of dna immunostimulatory sequence activity
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
JP6875683B2 (ja) * 2015-05-19 2021-05-26 国立研究開発法人国立精神・神経医療研究センター 多発性硬化症(ms)患者の新規治療適用判断方法
JP2021042670A (ja) 2016-11-07 2021-03-18 パナソニック株式会社 密閉型電動圧縮機及びこれを用いた冷凍装置

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BENJAMIN J. MECKIFF ET AL.: ""Single-Cell Transcriptomic Analysis of SARS-CoV-2 Reactive CD4 + T Cells"", SSRN ELECTRONIC JOURNAL, JPN6026016260, 2020, ISSN: 0005849410 *
JENNY HUANG ET AL.: ""ELISpot and ELISA analyses of human IL-21-secreting cells: Impact of blocking IL-21 interaction wi", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 417, JPN6026016257, February 2015 (2015-02-01), pages 60 - 66, ISSN: 0005849408 *
Y LONG ET AL.: ""Activated inducible co-stimulator-positive programmed cell death 1-positive follicular helper T ce", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 202, no. 1, JPN6026016258, 28 July 2020 (2020-07-28), pages 106 - 118, ISSN: 0005849409 *

Also Published As

Publication number Publication date
CN117441103A (zh) 2024-01-23
WO2022196701A1 (ja) 2022-09-22
EP4310171A4 (en) 2025-04-02
EP4310171A1 (en) 2024-01-24
US20240159738A1 (en) 2024-05-16

Similar Documents

Publication Publication Date Title
BR102021013306B1 (pt) Disposição introduzida em forno de pizza, com dispostivo de regulagem de altura da esteira com ajustes gradual escalonado
BR102021010384B1 (pt) Equipamento para limpeza e/ou teste de bicos injetores com alta pressão
BR102021007825B1 (pt) Equipamento de entretenimento e contemplação visual por cabines rotacionais e com giro radial e axial de 360 graus, para instalação em coberturas de edificações, penhascos ou encostas de elevações geográficas abissais
BR102021006565B1 (pt) Máquina de acabamento de estradas e método para operar a mesma
BR102021005700B1 (pt) Selo irregular para redução de ruído em aeronaves
BR102021005383B1 (pt) Método de perfurar um furo de poço marítimo com circulação reversa de fluido sem uso de tubulares de riser de perfuração
BR102021004908B1 (pt) Equipamento gerador de dióxido de cloro com processamento em alta pressão em reator com três zonas de operação para tratamento de águas e efluentes
BR102021003589B1 (pt) Método para fabricar uma estrutura monolítica em formato de caixa para fuselagens e asas de aeronave usando um material prepreg de matriz de polímero reforçada com fibra
BR102021003353B1 (pt) Aerofólio compósito estrutural, aeronave e método de montagem de um aerofólio compósito estrutural
BR102021002172B1 (pt) Sistema de trem de pouso, métodos de retração e de implantação de um sistema de trem de pouso
BR102021000474B1 (pt) Aparelho de pino de medição, sistema de amortecimento multiator, e, conjunto de amortecedor de impacto
BR102020026775B1 (pt) Montagem de painel de malha de arame soldado e uma ou mais armações, e parede ou teto reforçado por uma ou mais montagens
BR102020026454B1 (pt) Membrana de nanocelulose bacteriana e seu uso como bolus em radioterapia
BR102020026302B1 (pt) Processo de produção de corante natural azul
BR102020023974B1 (pt) Revestimento de amarras para redução de arrasto longitudinal
BR102020021170B1 (pt) Composição, formulações orais e uso
BR102020018864B1 (pt) Grade de ventilação modular
BR102020018483B1 (pt) Dispositivo mecânico para arraste de cabeçote móvel para realização de furos, alargamentos, roscas com machos por intermédio de automatização em tornos mecânicos horizontais
BR102020010912B1 (pt) Aparelho compacto de eletrólise de baixo custo
BR102020007524B1 (pt) Sistema de montagem e controle de acumuladores em estações de trabalho
BR102020005641B1 (pt) Método integrado de cultura do peixe lambari-do-rabo-amarelo, camarão-da-amazônia e o peixe curimbatá
BR102020003823B1 (pt) Distribuidor de corretivos, fertilizantes e sementes
BR102021009685B1 (pt) Processo de produção de termofosfato por sinterização via sopro
BR102021013929A2 (cg-RX-API-DMAC7.html)
BR102021012571A2 (cg-RX-API-DMAC7.html)

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250313

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20251016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260428

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260626